|
2025
|
Invention
|
Use of cd8-targeted viral vectors.
Provided herein are methods of transducing resting or non-act... |
|
|
Invention
|
Viral particles with fusogen display and related compositions and methods. Provided herein are li... |
|
|
Invention
|
Safety switches to control in vitro and in vivo proliferation of cell therapy products.
The pres... |
|
|
Invention
|
Safety switches to control in vitro and in vivo proliferation of cell therapy products. The prese... |
|
2024
|
Invention
|
Gprc5d-specific antibody constructs and compositions thereof.
Disclosed herein are antibodies or... |
|
|
Invention
|
Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell ... |
|
|
Invention
|
Method of screening a sample comprising a transgene with a unique barcode. The present disclosure... |
|
|
Invention
|
Modified cd47 proteins and their uses. The present disclosure provides engineered CD47 proteins a... |
|
|
Invention
|
Tandem fusogens and related lipid particles. Provided herein are lipid particles containing at le... |
|
|
Invention
|
Methods of delivery of islet cells and related methods. Provided herein are methods related to de... |
|
|
Invention
|
Methods of dosing and administration of engineered islet cells. Provided herein are methods of do... |
|
|
Invention
|
Anti-cd19 car t cells for treating b-cell malignancies and autoimmune diseases. The present discl... |
|
|
Invention
|
Digital droplet based assay for detecting replication competent lentiviral vector. Among other th... |
|
|
Invention
|
Lentiviral vectors with two or more genomes. Among other things, provided are an engineered lenti... |
|
|
Invention
|
Engineered protein g fusogens and related lipid particles and methods thereof. Provided herein ar... |
|
|
Invention
|
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses. Pr... |
|
|
Invention
|
Methods and compositions for modulating car-t activity.
Disclosed herein are engineered cells an... |
|
|
Invention
|
Identification of novel safe harbor sites for the stable expression of fusogen lentiviral vector.... |
|
|
Invention
|
Process for viral vector production. Among other things, provided are compositions and methods fo... |
|
|
Invention
|
Cd19-specific antibody constructs and compositions thereof. Disclosed herein are antibodies or an... |
|
|
Invention
|
Type-1 diabetes autoimmune mouse. Among other things, provided are non-human animals comprising i... |
|
2023
|
Invention
|
Bcma-specific antibody constructs and compositions thereof. Disclosed herein are antibodies or an... |
|
|
G/S
|
Cells for medical or clinical purposes; pharmaceutical preparations for use in cell therapy for m... |
|
|
G/S
|
Cells for medical or clinical purposes; pharmaceutical preparations for cell therapy for use in m... |
|
|
Invention
|
Cd4-specific antibody constructs and compositions and uses thereof.
Disclosed herein are antibod... |
|
|
Invention
|
Cytokine receptor agonist and viral vector combination therapies.
Provided herein are methods of... |
|
|
Invention
|
Engineered cd47 proteins and uses thereof.
The present disclosure provides engineered CD47 prote... |
|
|
Invention
|
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells.
Discl... |
|
|
Invention
|
Methods of repeat dosing and administration of lipid particles or viral vectors and related syste... |
|
|
Invention
|
Cd3-targeted lentiviral vectors and uses thereof.
Provided herein are methods of transducing T c... |
|
|
Invention
|
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related syst... |
|
|
Invention
|
Hypoimmune beta cells differentiated from pluripotent stem cells and related uses and methods.
P... |
|
2022
|
Invention
|
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods.
... |
|
|
Invention
|
Modified paramyxoviridae fusion glycoproteins.
Provided herein are lipid particles, such as lent... |
|
|
Invention
|
Modified paramyxoviridae attachment glycoproteins.
Provided herein are lipid particles, such as ... |
|
|
Invention
|
Methods and systems of particle production.
Provided herein are methods of producing lipid membr... |
|
|
Invention
|
Methods and reagents for amplifying viral vector nucleic acid products.
Provided herein are meth... |
|
|
Invention
|
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated composit... |
|
|
Invention
|
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammat... |
|
|
Invention
|
Engineering cells for cell-based therapies, and associated compositions and methods.
Provided ar... |
|
|
Invention
|
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory... |
|
|
Invention
|
Genetically modified cells for allogeneic cell therapy.
Provided are engineered cells containing... |
|
|
Invention
|
Use of cd4-targeted viral vectors.
Provided herein are methods of transducing resting or non-act... |
|
|
Invention
|
Polycistronic vectors for cell-based therapies.
Provided are polycistronic vectors for co-expres... |
|
|
Invention
|
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells.
Disclosed herein ar... |
|
|
Invention
|
Cryogenic storage racks and associated systems, devices, and methods.
Cryogenic storage racks (“... |
|
|
Invention
|
Cryogenic cassettes and associated systems, devices, and methods.
Cryogenic cassettes (“cryocass... |
|
|
Invention
|
Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein ... |
|
|
Invention
|
Hypoimmunogenic cells comprising engineered hla-e or hla-g.
Disclosed herein are engineered cell... |
|
|
Invention
|
Hypoimmunogenic rhd negative primary t cells.
Disclosed herein are hypoimmunogenic T cells havin... |
|
2021
|
Invention
|
Methods for triggering safety killing mechanisms using a cd47-sirpalpha blockade agent.
The pres... |
|
|
Invention
|
Cryogenic vial storage rack assembly |
|
2019
|
G/S
|
Cells for medical or clinical purposes, namely, human blood cells, human stem cells, human pancre... |
|
|
G/S
|
Cells for medical or clinical purposes; pharmaceutical
preparations for cell therapy for medical... |
|
2018
|
G/S
|
Scientific laboratory services, namely, blood processing services, namely, processing blood to be... |
|
|
G/S
|
Cells for cell or gene therapy for medical or clinical purposes; pharmaceutical preparations for ... |
|
|
G/S
|
Scientific laboratory services, namely, blood processing services, namely, processing patients' b... |
